Qianhai Health Holdings Limited (0911.HK)
HKD 0.27
(0.0%)
HKD 0.27
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 487 Thousand HKD | -58.97% |
| 2022 | 1.18 Million HKD | -84.84% |
| 2021 | 7.83 Million HKD | -67.46% |
| 2020 | 24.06 Million HKD | -68.53% |
| 2019 | 76.46 Million HKD | 47988.68% |
| 2018 | 159 Thousand HKD | -98.96% |
| 2017 | 15.28 Million HKD | 4381.52% |
| 2016 | 341 Thousand HKD | -99.98% |
| 2015 | 1.56 Billion HKD | -5.07% |
| 2014 | 1.64 Billion HKD | 350.67% |
| 2013 | 365.81 Million HKD | 0.0% |
| 2012 | - HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - HKD | -100.0% |
| 2024 Q2 | 123 Thousand HKD | 0.0% |
| 2023 Q3 | - HKD | -100.0% |
| 2023 Q1 | 123 Thousand HKD | -89.64% |
| 2023 FY | 487 Thousand HKD | -58.97% |
| 2023 Q2 | 841 Thousand HKD | 583.74% |
| 2023 Q4 | 487 Thousand HKD | 0.0% |
| 2022 FY | 1.18 Million HKD | -84.84% |
| 2022 Q4 | 1.18 Million HKD | 143.74% |
| 2022 Q3 | 487 Thousand HKD | 59.15% |
| 2022 Q2 | 306 Thousand HKD | 0.0% |
| 2022 Q1 | - HKD | -100.0% |
| 2021 FY | 7.83 Million HKD | -67.46% |
| 2021 Q4 | 7.83 Million HKD | 9.3% |
| 2021 Q2 | 19.44 Million HKD | 3.8% |
| 2021 Q3 | 7.16 Million HKD | -63.15% |
| 2021 Q1 | 18.73 Million HKD | -22.16% |
| 2020 Q3 | 23.37 Million HKD | -16.48% |
| 2020 FY | 24.06 Million HKD | -68.53% |
| 2020 Q2 | 27.98 Million HKD | 3.48% |
| 2020 Q1 | 27.04 Million HKD | -64.63% |
| 2020 Q4 | 24.06 Million HKD | 2.97% |
| 2019 FY | 76.46 Million HKD | 47988.68% |
| 2019 Q4 | 76.46 Million HKD | 1.28% |
| 2019 Q3 | 75.49 Million HKD | 120.45% |
| 2019 Q1 | 31.72 Million HKD | 19854.72% |
| 2019 Q2 | 34.24 Million HKD | 7.94% |
| 2018 Q1 | 114 Thousand HKD | -99.25% |
| 2018 FY | 159 Thousand HKD | -98.96% |
| 2018 Q4 | 159 Thousand HKD | 133.82% |
| 2018 Q3 | 68 Thousand HKD | -66.83% |
| 2018 Q2 | 205 Thousand HKD | 79.82% |
| 2017 Q1 | 205 Thousand HKD | -39.88% |
| 2017 Q2 | 296 Thousand HKD | 44.39% |
| 2017 FY | 15.28 Million HKD | 4381.52% |
| 2017 Q3 | 15.19 Million HKD | 5032.09% |
| 2017 Q4 | 15.28 Million HKD | 0.6% |
| 2016 FY | 341 Thousand HKD | -99.98% |
| 2016 Q4 | 341 Thousand HKD | 36.4% |
| 2016 Q3 | 250 Thousand HKD | -99.95% |
| 2016 Q2 | 468.66 Million HKD | 0.08% |
| 2016 Q1 | 468.27 Million HKD | -70.08% |
| 2015 Q3 | 1.56 Billion HKD | -13.03% |
| 2015 Q2 | 1.79 Billion HKD | 0.03% |
| 2015 Q1 | 1.79 Billion HKD | 9.11% |
| 2015 FY | 1.56 Billion HKD | -5.07% |
| 2015 Q4 | 1.56 Billion HKD | 0.01% |
| 2014 Q2 | 292.51 Million HKD | 0.4% |
| 2014 Q1 | 291.35 Million HKD | -20.36% |
| 2014 Q3 | 1.64 Billion HKD | 463.23% |
| 2014 Q4 | 1.64 Billion HKD | 0.07% |
| 2014 FY | 1.64 Billion HKD | 350.67% |
| 2013 Q4 | 365.81 Million HKD | 0.37% |
| 2013 FY | 365.81 Million HKD | 0.0% |
| 2013 Q1 | - HKD | 0.0% |
| 2013 Q3 | 364.48 Million HKD | 0.0% |
| 2012 FY | - HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | 92.849% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 99.986% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 99.596% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 99.894% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 99.761% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 99.834% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 99.854% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 99.885% |
| SSY Group Limited | 3.37 Billion HKD | 99.986% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 99.635% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 99.935% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.999% |